摘要
目的分析心力衰竭患者同时服用美托洛尔、厄贝沙坦的作用价值。方法随机选取2022年6月—2023年6月聊城市第四人民医院收治的100例慢性心力衰竭患者为研究对象。依据随机抽签法分为两组,每组50例。对照组采用厄贝沙坦单一用药治疗,观察组采用厄贝沙坦+美托洛尔治疗,治疗周期均为3个月。比较两组患者临床疗效、心功能指标、6 min步行试验(6-minute Walking Test,6MWT)和药物不良反应发生率。结果观察组治疗总有效率(92.00%)高于对照组(74.00%),差异有统计学意义(χ^(2)=5.740,P<0.05)。治疗前,两组患者心功能指标和6MWT比较,差异无统计学意义(P均>0.05),治疗后,观察组左室舒张末期内径、左室收缩末期内径低于对照组,左室射血分数与6MWT高于对照组,差异有统计学意义(P均<0.05)。两组患者治疗不良反应发生率比较,差异无统计学意义(P>0.05)。结论将厄贝沙坦+美托洛尔作为治疗慢性心力衰竭的药物方案,可进一步提升临床疗效,促进心功能和6MWT的提高,具备良好药物安全性。
Objective To analyze the value of the effect of simultaneous administration of metoprolol,irbesartan in pa⁃tients with heart failure.Methods 100 cases of chronic heart failure patients treated in Liaocheng Fourth People's Hospital from June 2022 to June 2023 were randomly selected as the study objects.They were divided into two groups based on the random draw method,with 50 cases in each group.The control group was treated with irbesartan single drug,and the observation group was treated with irbesartan+metoprolol,and the treatment period was 3 months.The clinical efficacy,cardiac function indexes,6-minute Walking Test(6MWT)and the incidence of adverse drug reac⁃tions were compared between the two groups.Results The total effective rate of treatment in the observation group was 92.00%,which was higher than 74.00%in the control group,and the difference was statistically significant(χ^(2)=5.740,P<0.05).Before treatment,compared with the cardiac function indexes and 6MWT of the two groups of patients,the difference was not statistically significant(all P>0.05),after treatment,the left ventricular end-diastolic internal diam⁃eter and left ventricular end-systolic internal diameter of the observation group were lower than those of the control group,and the left ventricular ejection fraction and 6MWT were higher than those of the control group,and the differ⁃ences were statistically significant(all P<0.05).Comparing the incidence of adverse effects of treatment between the two groups,the difference was not statistically significant(P>0.05).Conclusion Using irbesartan+metoprolol as a drug regimen for the treatment of chronic heart failure can further enhance the clinical efficacy,promote the improve⁃ment of cardiac function and 6MWT,and possess good drug safety.
作者
孟淑荣
MENG Shurong(Liaocheng Fourth People's Hospital,Liaocheng,Shandong Province,252000 China)
出处
《中外医疗》
2024年第15期68-70,74,共4页
China & Foreign Medical Treatment
关键词
慢性心力衰竭
美托洛尔
厄贝沙坦
心功能
临床疗效
不良反应
Chronic heart failure
Metoprolol
Irbesartan
Cardiac function
Clinical efficacy
Adverse effects
